Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Aug 30;32(19):3332-41.
doi: 10.1002/sim.5750. Epub 2013 Jan 31.

A note on the catch-up time method for estimating lead or sojourn time in prostate cancer screening

Gerrit Draisma  1 , Joost van Rosmalen
Affiliations
Comparative Study

A note on the catch-up time method for estimating lead or sojourn time in prostate cancer screening

Gerrit Draisma et al. Stat Med. .

Abstract

Models of cancer screening assume that cancers are detectable by screening before being diagnosed clinically through symptoms. The duration of this preclinical phase is called sojourn time, and it determines how much diagnosis might be advanced in time by the screening test (lead time). In the catch-up time method, mean sojourn time or lead time are estimated as the time needed for cumulative incidence in an unscreened population to catch up with the detection rate (prevalence) at a first screening test. The method has been proposed as a substitute of the prevalence/incidence ratio in the case of prostate cancer where incidence cannot be treated as a constant. A model is proposed to justify this estimator. It is shown that this model is different from classic Markov-type models developed for breast cancer screening. In both models, the catch-up time method results in biased estimates of mean sojourn time.

Keywords: cancer screening; lead time; prostate cancer; sojourn time.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The catch-up time estimate for mean sojourn time. The graph shows the cumulative incidence of prostate cancer in the control arm from study entry in the Rotterdam section of ERSPC. The horizontal line represents the prevalence (4%) of preclinical prostate cancer at the first screening test. Cumulative incidence in the control arm catches up with prevalence after 8.16 years. The dashed line represents the quadratic approximation of cumulative incidence, 0.0034342704x + 0.0001796227x2 used in the numerical example. Figure adapted from Finne et al. .
Figure 2
Figure 2
Relevant variables in screening models. Screening at time t may detect cancers with time of clinical diagnosis X > t and sojourn time Y > X − t, that is, with onset of preclinical disease Z < t. In case of detection, diagnosis has been advanced with lead time L.
Figure 3
Figure 3
Prostate cancer incidence after a screening test with sensitivity 1.0 as predicted by the classic model (13) with μ = 11.64 and the catch-up time model (14) with mean sojourn time μ = 6.80 compared with background incidence without screening. Background incidence as given in Figure 1.
See this image and copyright information in PMC

References

    1. Zelen M, Feinleib M. On the theory of screening for chronic diseases. Biometrika. 1969;56:601–614.
    1. Day N, Walter S. Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics. 1984;40(1):1–14. PMID: 6733223. - PubMed
    1. Auvinen A, Määttänen L, Stenman U, Tammela T, Rannikko S, Aro J, Juusela H, Hakama M. Lead-time in prostate cancer screening (Finland) Cancer Causes Control. 2002;13(3):279–285. PMID: 12020110. - PubMed
    1. Finne P, Fallah M, Hakama M, Ciatto S, Hugosson J, de Koning H, Moss S, Nelen V, Auvinen A. Lead-time in the European Randomised Study of Screening for Prostate Cancer. European Journal of Cancer. 2010;46(17):3102–3108. PMID: 21047593. - PubMed
    1. Pashayan N, Duffy S, Pharoah P, Greenberg D, Donovan J, Martin R, Hamdy F, Neal D. Mean sojourn time, overdiagnosis and reduction in advances stage prostate cancer due to screening with PSA: implication of sojourn time on screening. British Journal of Cancer. 2009;100(7):1198–1204. PMID:19293796. - PMC - PubMed

Publication types

LinkOut - more resources